A
Alume Biosciences
On a mission to make proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit
About Alume Biosciences
Alume Biosciences is a biotechnology company that develops nerve-targeted drugs to improve surgical precision and preserve nerve function. The company's lead product, Bevonescein (ALM-488), is a peptide-dye conjugate designed to illuminate nerves during surgery, which is currently in Phase 3 clinical trials.
Alume Biosciences operates in the surgical and therapeutic pharmaceutical market, with a focus on providing solutions for surgeons to protect and preserve nerve function. The company's business model is centered around the development and commercialization of its proprietary nerve illumination technology. Alume Biosciences has secured $13 million in Series B financing to advance the clinical development of Bevonescein.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2023 | $13M | $52M | Undisclosed | ↗ |
| GRANTOther financing | Sep 2022 | $3.4M | — | National Institute of Neurological Disorders and Stroke | ↗ |
Growth signals
Latest recorded traffic for Alume Biosciences is 1.7K monthly website visits, up 41.7% over the last three months. Alume Biosciences's team declined 10.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alume Biosciences in the San Diego ecosystem
The Alume Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Small Business Innovation Research
National Institute of Neurological Disorders and Stroke
Other known investors2 additional known investors
University of California, San Diego- BIBioBrit
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alume Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alume Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









